Same news on the wire today:
SOUTH SAN FRANCISCO, Calif. , Aug 9, 2012 -- Talon Therapeutics today announced Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. This indication is based on overall response rate. Clinical benefit such as improvement in overall survival has not been verified. Marqibo is administered at a dose of 2.25 mg/m2 intravenously over 1 hour once every 7 days. Marqibo has different dosage recommendations than non-liposomal vincristine sulfate.
"We are delighted that Marqibo will be available to a patient population with an underserved hematologic malignancy," stated Steven R. Deitcher MD, President, Chief Executive Officer and Board Member of Talon Therapeutics . "This represents a transformational event for Talon and fulfillment of our most important corporate goal, to date."
Conference Call Scheduled for Friday, August 10 at 12:00pm EDT , 9:00am PDT
Market Data 
Markets 
AI
